Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care

HIV Clinical Trial

Official title:

Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01900080
• Other study ID #: AI104344-01A1
• Status: Active, not recruiting
• Phase: N/A
• First received: July 12, 2013
• Last updated: October 10, 2016
• Start date: August 2013
• Est. completion date: January 2017

Study information

• Verified date: October 2016
• Source: Brigham and Women's Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Haiti: Institutional Review BoardUnited States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if same-day HIV testing and antiretroviral therapy (ART) initiation improves retention in care (as measured by the proportion of participants who are alive and in-care with an undetectable viral load 12 months after HIV testing), compared with standard of care (three visits prior to ART initiation). Secondary outcomes include survival, ART initiation, retention in care with viral load < 200 and < 1000 copies/ml, 6-month viral load, and adherence as measured by self-report and pharmacy refill records. Enrollment for the main study was completed in October 2015.

In June 2015, enrollment was started for a new sub-study. This sub-study, funded by MAC AIDS, includes patients with WHO stage 1 or 2 disease and CD4 count >500 cells/mm3. The purpose of the sub-study is to compare 6-month retention for patients who receive same-day ART vs. standard pre-ART care. Secondary outcomes include adherence to INH and Bactrim, and cost-effectiveness between the two groups. Enrollment for the sub-study is ongoing.

Description:

This study is a randomized trial to establish the effectiveness of same-day ART initiation for patients who present for HIV testing with early HIV clinical disease (World Health Organization [WHO] stage 1 or 2) who qualify for ART by immunologic criteria (CD4 cell count ≤500 cells/mm3) with rapid CD4 cell testing at the GHESKIO Center in Port-au-Prince, Haiti. All patients in the intervention group received rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for opportunistic infections, WHO staging, comprehensive counseling and social support, and ART initiation on the day of presentation. The standard group received the same services as the same-day ART group (including CD4 cell testing) except that instead of same-day ART, they received the standard GHESKIO protocol of three sequential visits for ART readiness counseling and testing for opportunistic infections prior to ART initiation. For the same-day ART group, these activities took place on the day of ART initiation and during the subsequent two weeks. Three specific aims are proposed. The first aim is to compare the proportion of patients in the standard and same-day ART groups that are alive and in-care with an undetectable HIV viral load at 12 months after HIV testing. The second aim is to compare six-month ART adherence between the two groups using pharmacy refill records. The third aim is to compare the cost and cost-effectiveness of standard and same-day ART, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with an undetectable viral load at 12 months after HIV testing.

In a sub-study funded by MAC AIDS Foundation (enrollment started June 2015), patients with WHO stage 1 or 2 disease and CD4 count >500 cells/mm3 were included. They are being randomized to receive ART vs. standard pre-ART care. Participants are being enrolled in the study on the same day they receive CD4 count results, which is within 7 days of the date of HIV testing. All patients will receive additional tests as clinically indicated. All participants will receive prophylactic treatment with trimethoprim-sulfamethoxazole and isoniazid, and a daily multivitamin, as is standard of care at GHESKIO. Participants who are randomized to the standard pre-ART group will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits. They will have a CD4 count annually, and start ART when they meet WHO criteria. Participants who are randomized to the same-day ART group will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 814
• Est. completion date: January 2017
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Age =18 years;

• Ability and willingness of participant to give written informed consent;

• CD4 cell count </=500 cells/mm3

• WHO stage 1 or 2 disease as defined by the following conditions: Asymptomatic; Persistent generalized lymphadenopathy; Moderate unexplained weight loss (under 10% of presumed or measured body weight); Recurrent upper respiratory tract infections (sinusitis, tonsillitis, otitis media, pharyngitis); Herpes zoster; Angular cheilitis; Recurrent oral ulcerations; Papular pruritic eruptions; Seborrheic dermatitis; Fungal nail infections

Exclusion Criteria:

• Any use of ART in the past;

• Pregnancy or breastfeeding at the screening visit;

• Psychologically unprepared to start ART, based on ART readiness survey;

• Plans to transfer care to another clinic during the study period;

• WHO stage 3 or 4 disease.

Note: For the sub-study that includes patients with WHO stage 1 or 2 disease and CD4 count >500, the inclusion and exclusion criteria are the same; only CD4 count is different.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV

Intervention

Other:
• Same-Day HIV testing and ART initiation
Same-day HIV testing and ART initiation
• Standard ART Initiation
Standard ART Initiation
• Sub-Study: Same-Day ART, CD4 Count >500
Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
• Sub-Study: Standard Pre-ART Care, CD4 Count >500
Standard pre-ART care for patients with CD4 count >500 cells/mm3

Locations

Country	Name	City	State
Haiti	Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO)	Port-au-Prince

Sponsors (5)

Lead Sponsor	Collaborator
Brigham and Women's Hospital	Florida International University, Haitian Group for the Study for Kaposi’s Sarcome and Opportunistic Infections, Harvard Medical School, Weill Medical College of Cornell University

Country where clinical trial is conducted

Haiti, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Cost-effectiveness	To compare the cost and cost-effectiveness of standard and same-day ART, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with a plasma HIV-1 RNA level <50 copies/ml at 12 months after HIV testing	12 months after HIV testing	No
Other	Retention with undetectable viral load at <200 copies/ml and <1000 copies/ml cut-off points	Proportion of participants who are alive and in care with a plasma HIV-1 RNA level <200 copies/ml and <1000 copies/ml	6 and 12 months after HIV testing	No
Other	ART initiation	Proportion of participants who initiate ART during the study period	12 months	No
Other	Time to Death or LTFU	Median time to death or LTFU	12 months	No
Primary	Retention in care with undetectable viral load	Proportion of patients who are alive and in-care with a plasma HIV-1 RNA level <50 copies at 12 months after HIV testing	12 months after HIV testing	No
Secondary	Adherence to antiretroviral therapy (ART), measured by pharmacy refill records and self-report	Comparison of adherence for the first 6 months of ART between the two groups using pharmacy refill records and 3-day self-report	6 months after ART initiation	No